Electrode array with prolonged release of DXM improved short-term preservation of residual hearing after implantation for the frequencies 500, 1000, 4000, and 16 000 Hz in gerbils. The long-term results at 1 year confirmed these data for higher frequencies, but must be verified for the lower frequencies of 500 and 1000 Hz.

No abstract

Bilateral thymectomy risk outweighs any likely carcinologic benefit. We do not recommend routine bilateral thymectomy during central neck dissection for differentiated thyroid cancer.

About 20% of OPA1 mutation carriers have complicated forms of dominant optic atrophy associating extra‐ocular features. Reviewing the files of 327 patients with an OPA1 mutation, we found 21 deaf patients (6.4%). In 10 patients deafness was detected under age 20, in 3 patients over age 20 and in 8 patients the age of onset was unknown. The severity of deafness ranged from mild and moderate. Audiological tests supported the diagnosis of auditory neuropathy in 8 cases. Seven different OPA1 mutations were identified in deaf patients. Three mutations, p.Arg445His, p.Gly401Asp and p.Leu243*, have been previously reported in patients with deafness. Two mutations, p.Val291_Phe328del and p.Ile463_Phe464dup, have been reported in patients with DOA without deafness. Finally, two novel OPA1 mutations, p.Arg437Glu and p.Ala357Leufs*4 were found. In the majority of patients with DOA and deafness, visual impairment occurred during the first decade while deafness appeared later. However, in 54% of patients deafness started prior to visual abnormalities. These observations suggest that audition should be carefully tested, including a specific search for auditory neuropahy in OPA1 mutation carriers.